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Abstract KW-2228 is a tailored human granulocyte colony-
stimulating factor (hG-CSF) which has more potent granulo-
poietic activity and o is more stable than wild-type hG-CSF. 
Analysis of the 2.3 A resolution crystal structure of KW-2228 
unambiguously revealed a four-a-helix bundle motif with up-up-
down-down connectivity. The structures of long overhand loops 
connecting the helices and the N-terminus have been definitively 
determined. The present analysis has clearly revealed that 
substituted residues play important roles in fastening a long 
overhand loop to the N- and C-termini to fix the conformation. 
This conformation should be responsible for a substantial 
enhancement of the biological activity and stability. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Colony-stimulating factors (CSFs) are a family of glycopro-
teins that stimulate the proliferation and differentiation of 
hematopoietic cells in vivo. These proteins include granulo-
cyte colony-stimulating factor (G-CSF), granulocyte-macro-
phage colony-stimulating factor (GM-CSF), macrophage 
colony-stimulating factor (M-CSF), interleukins and erythro-
poietin [1]. Human G-CSF (hG-CSF) is a 19.6-kDa glycopro-
tein consisting of 174 amino acid residues [2]. One O-linked 
glycosyl group is attached to hG-CSF at Thr133. This group 
contributes to the stability of the molecule but does not 
influence its binding to receptors [3]. G-CSF, produced mainly 
by macrophages, stimulates neutrophilic granulocyte colony 
formation from bone marrow stem cells and induces the ter-
minal differentiation of leukemic cells [4]. hG-CSF has been 
isolated from tumor cells [5] and its cDNAs have been cloned 
[2]. One of the two cDNAs which encodes 174 amino acid 
residues was isolated from a cDNA library of lipopolysac-
charide-stimulating human peripheral blood macrophages 
[6]. The recombinant hG-CSF has been found to be useful 
in the treatment of 5-fluorouracil-induced hematopoietic in-
jury in mice [7]. More than 100 novel hG-CSFs have been 
engineered with the aim of identifying novel proteins with 
enhanced biological activity and physicochemical properties 
[8]. One of these engineered proteins, designated KW-2228, 
has more potent granulopoietic activity than that of wild-
type hG-CSF, both in vitro and in vivo [8,9]. KW-2228 
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(Neu-up) is currently being used clinically and is yielding 
very satisfactory results. Thr1, Leu3, Gly4, Pro5 and Cys17 
in wild-type hG-CSF are replaced by Ala, Thr, Tyr, Arg 
and Ser, respectively, in KW-2228. KW-2228 was also found 
to be more stable both physicochemically and biologically 
than wild-type hG-CSF, especially in phosphate-buffered sal-
ine at 56°C and in human plasma at 37°C [9]. It is essential to 
determine the three-dimensional structure of KW-2228 to 
understand the mechanism underlying its high potency and 
stability, and thus we have undertaken X-ray analysis of 
KW-2228 [10]. Recently the crystal structures of native canine, 
bovine and human G-CSFs have been published [11,12]. 
These three G-CSFs show about 80% sequence similarity 
and share the same four-a-helix bundle motif with up-up-
down-down connectivity. In these molecular models, however, 
the positions of more than 9% of the amino acid residues 
could not be located due to poor electron density, in partic-
ular the missing residues in hG-CSF range 1-7, 61-69, 126-
135 and 172-17. They account for almost 16% of all the 
residues. Thus the published molecular model of hG-CSF 
[11] is incomplete, and we need a complete molecular model 
to be able to fully elucidate the structure-function relation-
ships. In this paper we report on a crystal structure of KW-
2228 in which the positions of 98% of the amino acid residues 
are located. Based on the structure of G-CSF which has been 
determined, the mechanism underlying the high potency and 
stability of KW-2228 will be discussed. 
2. Materials and methods 
KW-2228 was crystallized as described elsewhere [10]. We obtained 
at least three polymorphs, but in the present analysis we used crystals 
which belong to the monoclinic space group C2 with lattice constants 
a = 82.0, b = 49.2, c = 49.4 A, and (3=113.9° and diffract to 2.0 A 
resolution. The asymmetric unit consists of one monomer with a 
solvent content of 49%. The 2.0 A resolution data set for the native 
crystal was collected at the beamline BL6A of the Photon Factory 
(Tsukuba, Japan) by use of monochromatized radiation at X= 1.04 A. 
The intensity data were collected on a screenless Weissenberg camera 
for macromolecules [13] with Fuji imaging plates (Fuji Film Co. Ltd.). 
The data were processed with WEIS [14] and scaled with PROTEIN 
[15]. A 1.7 A resolution model of bovine G-CSF[11] was positioned in 
the asymmetric unit by molecular replacement (MR) using X-plor 
[16], The top rotation function solution gave a peak which was twice 
as high as the second-highest one. The model which was constructed 
based on the top translation function solution was improved by rigid 
body refinement, and the crystallographic R factor for this model was 
46.5% (10-3 A). The MR phases were further improved by solvent 
flattening and density histogram matching using SQUASH [17]. X-
plor was used to calculate maps, which were fitted using Turbo-FRO-
DO [18]. The initial model gave an R-factor of 48.5%. The standard 
simulated annealing procedure of X-plor was used for the refinement. 
After several cycles of model building, water addition, and energy 
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Fig. 1. The schematic drawing of the secondary structure elements 
of KW-2228. The rectangles mark a-helices. A, B, C, D and E heli-
ces are labeled according to Scheme 1. 
minimizations, the final model was obtained. The final refined model 
yielded a crystallographic R-factor of 21.5%, including all data from 
8.0-2.3 A. The r.m.s. deviations from ideal bond lengths and angles 
are 0.022 A and 3.70°. Residues Thr3, Pro132 and Pro174 are flexible 
and show low electron density. The figures in this paper were created 
with MOLSCRIPT [19]. Final coordinates will be deposited in the 
Brookhaven Data Bank. 
3. Results 
The main structural feature of KW-2228 is an antiparallel 
four-oc-helix bundle (Figs. 1 and 2) which has a left-handed 
twist with overall dimensions of approximately 45x25x25 
A3. The a-helices, which are designated A through D, consist 
of residues 10-39, 73-92, 99-123, and 142-171, respectively. 
The overall topology of the bundle is very similar to those 
observed in bovine, canine and wild-type hG-CSFs and very 
close to that of an ideal left-handed antiparallel four-a-helix 
bundle. The four helices are connected by three loops desig-
nated AB, BC and CD. The AB and CD loops are long over-
hand connections, and the shortest loop, BC, joins helix B to 
helix C. In addition to the major helices there is a short ex-
tended 3 io helix designated E within the AB loop which con-
sists of residues 43-52. 
In the X-ray analysis of wild-type hG-CSF, the electron 
density for the N- and C-termini and the long overhand loops 
was poorly defined, and the coordinates of residues 1-8, 62-
70, 127-136 and 173-174 were not determined [11]. Therefore 
the topology of the connections between the four helices in 
hG-CSF is ambiguous. Even in the molecular model of crystal 
form II of canine G-CSF which is the G-CSF structure most 
accurately determined so far [11], the coordinates of residues 
1-7, 129-135 and 174 are not located clearly and the struc-
tures of the N-terminal region and the middle of the CD loop 
are not definitive. In the structure of KW-2228, however, the 
electron density is clearly defined and the positions of all of 
the residues except 1, 2, 130 and 131 are definitive. Although 
G-CSF is expected to be structurally flexible due to the pres-
ence of the remarkably long overhand loops, the substitution 
of amino acids at residues 1, 3, 4, 5 and 17 in KW-2228 has 
frozen the conformation and allowed us to determine almost 
the entire structure of hG-CSF for the first time. In bovine G-
CSF Ala93, Gly94 and He95 form almost one turn of a left-
handed helix, but in KW-2228 they are not in the region of 
the left-handed helix on the Ramachandran plot. 
There are two disulfide bridges in hG-CSF. The Cys64-
Fig. 2. Stereoscopic ribbon drawing of KW-2228. Helices A, B, C, D and E are shown in green, cyan, yellow, red and blue, respectively. 
/. Fujii et allFEBS Letters 410 (1997) 131-135 133 
L 3 1 ( A ) — L 1 0 3 ( C ) 
I 
V21(A) F l 13(C) 1 2 4 ( A ) L 1 0 6 < C ) — L 8 9 ( B ) - - - V 1 5 3 ( D ) ~ - L 8 8 <B) 
1 I 1 
L 8 2 ( B ) L 1 6 1 ( D ) L 1 5 7 ( D ) 
L 7 5 ( B ) 
L 7 1 ( B ' ) - - - L 9 ( A ' ) — F13(A) 1 1 1 7 ( C ) 
I 
L 1 2 4 ( C " ) 
L 1 8 ( A ) - - L 1 6 8 ( D ) 
L 3 5 ( A ) — L 9 9 ( C ) 195 ( B " ) 
I 
V151(D) 
L 4 1 ( A " ) — F 1 4 4 ( D ) 
L 6 1 ( A B ) V163(D) 
L 9 2 ( B ) F 1 4 0 ( D ' ) 
Scheme 1. Leucine-rich hydrophobic network. A, B, C, D and AB 
in parentheses denote the A, B, C and D helices and AB loop, 
respectively. ' and " indicate positions near the N- and C-termini, 
respectively: i.e., L9(A') means that L9 is located near the N-termi-
nus of helix A but not in helix A. Leucine residues are in bold 
type. Close contacts shorter than the sum of van der Waals radii 
are shown. 
Cys74 disulfide bridge is buried in the interior of the molecule, 
but the Cys36-Cys42 bridge is on the surface of the molecule. 
These disulfide bridges restrict the conformation of the long 
overhand AB connection. 
There is a specific hydrophobic network in the interior of 
the bundle which is markedly rich in leucine residues. Out of 
70 least solvent-accessible residues, approximately 33% are 
leucine residues. Many leucine residues together with some 
valine, isoleucine and phenylalanine residues constitute a net-
work (hereafter referred to as a 'leucine-rich hydrophobic net-
Fig. 3. Structure near the N-terminus displaying Y4, R5, A6,S7, L69, A172 and a water molecule (w329). Green, blue and red circles denote 
carbon, nitrogen and oxygen atoms, respectively. The broken lines indicate possible hydrogen bonds and an electrostatic interaction. 
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Fig. 4. Predicted receptor binding sites. Regions shown in red are recognized by different monoclonal anti-GCSF antibodies and exposed on 
the surface of G-CSF. 
work') as shown in Scheme 1. Seventeen out of 19 leucine 
residues in the leucine-rich hydrophobic network are less sol-
vent-accessible. The characteristic leucine-rich hydrophobic 
network obviously plays a very important role in stabilization 
of the four helices in the bundle configuration. In G-CSF 
there are particularly long overhand connections which are 
potentially flexible. Therefore the leucine-rich hydrophobic 
network may function as a scaffold to stabilize the bundle 
and adjust the positions of specific residues favorable for 
binding of receptors. 
4. Discussion 
The biological activity and stability of KW-2228 in human 
serum are markedly enhanced compared with those of wild-
type hG-CSF [8,9]. The residues which are engineered in KW-
2228 are located near the N-terminus. A water molecule des-
ignated w329 is located near the carbonyl oxygens of Ser7 and 
Leu69 with O-O distances of 3.11 and 3.10 A, respectively 
(Fig. 3). Pro5 in wild-type hG-CSF is replaced by Arg in 
KW-2228 and w329 is located near the carbonyl oxygen of 
Arg5. The distance between the oxygen atoms of w329 and 
Arg5 is 3.29 A and it can be a weak hydrogen bond. The 
positively charged Nr|2 atom of Arg5 is located near the car-
bonyl oxygen of Ala172 with an N—O distance of 4.08 A and 
electrostatic interaction occurring between them. In wild-type 
hG-CSF the positions of seven residues in the N-terminal 
region were not determined unequivocally and the position 
of Pro5 is unknown. The structure of the N-terminal region 
of KW-2228, however, clearly suggests that neither the car-
bonyl nor the amino group of Pro5 in wild-type hG-CSF 
approaches the water molecule and no interactions occur be-
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tween Pro5 and Ala172. The carbonyl group of Tyr4 is hydro-
gen-bonded to the amino group of Ala6 with an O—N distance 
of 2.90 A. The main chain conformation of Tyr4 could also be 
influenced significantly by the following residue. The specific 
network of interactions which involve Arg5 contribute stabi-
lization of the conformation of the N- and C-terminal regions 
and fix the middle of the long overhand AB connection. The 
structure of the sequence of residues 62-70 in wild-type hG-
CSF could not be determined, but in KW-2228 they adopt 
clear conformations. 
Cys17 is substituted by Ser in KW-2228. In wild-type hG-
CSF Cys17 is located in the interior of the molecule and sur-
rounded by hydrophobic residues but no specific interactions 
occur between Cys17 and surrounding residues. In KW-2228, 
however, the hydroxyl group of Ser17 forms a hydrogen bond 
with the carbonyl group of Leu14 (O—O distance of 3.10 A). 
The substitution may contribute to the stability of the protein. 
The present analysis has revealed that the mutations intro-
duced in KW-2228 contribute to the stabilization of the con-
formation of the molecule including the two long overhand 
connections. The significant enhancement of the physicochem-
ical and biological stability and biological activity of KW-
2228 is undoubtedly due to its stabilized active conformation. 
The binding of G-CSF to its receptor on pluripotent stem 
cells triggers terminal differentiation of the cells. Understand-
ing the binding mechanism is a prerequisite to designing an 
improved G-CSF. First we must determine the regions of G-
CSF that bind to the receptor. It is expected that residues that 
contribute to G-CSF receptor binding are located on the sur-
face of G-CSF. In KW-2228 the particularly solvent-accessible 
residues are present in the AB and CD loops and the E short 
helix. Most of the solvent-accessible residues are located on 
the same side of the molecule. Around the E short helix 8 of 
the 13 residues 43-55 are highly solvent-accessible. In the CD 
loop 6 of the 10 residues 131-140 are also highly solvent-
accessible. These 14 residues are on the same side of the mol-
ecule. Layton et al. prepared monoclonal anti-G-CSF anti-
bodies and mapped the regions of G-CSF recognized by dif-
ferent antibody groups [20]. They predicted that residues 20-
46 and the C-terminus bind to the G-CSF receptor. Residues 
138-142 are recognized by common antibodies. Based on the 
structural and biological information obtained to date, we 
predict that residues 43^16 and 138-140 and/or those near 
them are involved in G-CSF receptor binding (Fig. 4). 
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